capecitabine

Interviews and expert commentary tagged “capecitabine” — the latest oncology research and clinical practice from the Audio Journal of Oncology.

Audio Journal of Oncology Volume 16 Number 11
Audio Journal of Oncology

Audio Journal of Oncology Volume 16 Number 11

Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan) Sarah Maxwell and Peter Goodwin report from: American Society of Clinical Oncology

3 June 2008
0:00
Audio Journal of Oncology Volume 16 Number 10
Audio Journal of Oncology

Audio Journal of Oncology Volume 16 Number 10

Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan) Commenting Expert: Michael Untch, HELIOS Klinikum, Berlin In this edition Peter Goo

25 May 2008
0:00
Audio Journal of Oncology Volume 16 Number 9
Audio Journal of Oncology

Audio Journal of Oncology Volume 16 Number 9

Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan) Commenting Expert: Emiel Rutgers, Netherlands Cancer Institute, Amsterdam Angel Rod

26 April 2008
0:00
Oral Capecitabine: As Good As Fluorouracil Second Line for Metastatic Colorectal Cancer
Audio Journal of Oncology

Oral Capecitabine: As Good As Fluorouracil Second Line for Metastatic Colorectal Cancer

David Cunningham REFERENCE: Abstract 3012, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 DAVID CUNNINGHAM, Royal Marsden Hospital, London The oral agent capeticabine

15 February 2008
0:00
Two New Second-Line Options For Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Audio Journal of Oncology

Two New Second-Line Options For Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

Jean-Yves Douillard Gordon McVie REFERENCE: Abstracts: 6507 & 2LB, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 JEAN-YVES DOUILLARD, Centre René Gauducheau, N

16 November 2007
0:00
Neoadjuvant Trastuzumab: Marked Benefit in HER2-Positive Inflammatory Breast Cancer
Audio Journal of Oncology

Neoadjuvant Trastuzumab: Marked Benefit in HER2-Positive Inflammatory Breast Cancer

Jose Baselga Gordon McVie REFERENCE: ABSTRACT 2030, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 JOSE BASELGA, Vall d’Hebron University Hospital, Barcelona CO

16 October 2007
0:00
ASCO Audio Journal of Oncology – June 4th 2006, from the ASCO Annual Meeting in Atlanta, June 2-6; in the company of Julie Gralow
Audio Journal of Oncology

ASCO Audio Journal of Oncology – June 4th 2006, from the ASCO Annual Meeting in Atlanta, June 2-6; in the company of Julie Gralow

Julie Gralow Charles Geyer Judith Bliss Robert Coleman Julie Gralow, from the Fred Hutchinson Cancer Research Center in Seattle, joins Derek Thorne to talk about the latest news from the ASCO annual m

3 June 2006
0:00